About Nuclear pore complex-interacting protein family member A5
Nuclear pore complex-interacting protein family member A5 (NPIPA5) is a protein
from Homo sapiens identified by UniProt accession
E9PKD4, 350 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | Nuclear pore complex-interacting protein family member A5 |
| UniProt accession | E9PKD4 |
| Gene | NPIPA5 |
| Organism | Homo sapiens |
| Length | 350 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (18)
Diseases linked to this target (Open Targets).
- Moebius syndrome · score 0.11
- reticulocyte count · score 0.06
- glycerophospholipid measurement · score 0.06
- blood metabolite measurement · score 0.06
- triglyceride measurement · score 0.05
- diacylglycerol 38:3 measurement · score 0.04
- alkaline phosphatase measurement · score 0.04
- high density lipoprotein cholesterol measurement · score 0.03
- lean body mass · score 0.03
- sex hormone-binding globulin measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-E9PKD4-F1 | alphafold | PREDICTED | 51.72 | — |
Amino-acid sequence (350 residues)
MFCCLGYEWL SGGCKTWHSA WVINTLADHR HRGTDFGGSP WLLIITVFLR SYKFAISLCT SYLCVSFLKT IFPSQNGHDG STDVQQRARR SNCRRQEGIK IVLEDIFTLW RQVETKVRAK IRKMKVTTKV NRHDKINGKR KTAKEHLRKL SMKEREHGEK ERQVSEAEEN GKLDMKEIHT YMEMFQRAQA LRRRAEDYYR CKITPSARKP LCNRVRMAAV EHRHSSGLPY WPYLTAETLK NRMGHQPPPP TQQHSIIDNS LSLKTPSERL LYPLPPSADD NLKTPPECLL TPLPPSALPS ADDNLKTPAE CLLTPLPPSA PPSADDNLKT PPECVCSLPF HPQRMIISRN
Explore Nuclear pore complex-interacting protein family member A5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets